Sanofi Total Liabilities 2010-2024 | SNY

Sanofi total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Sanofi total liabilities for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Sanofi total liabilities for 2023 were $56.4B, a 3.8% increase from 2022.
  • Sanofi total liabilities for 2022 were $54.334B, a 10.32% decline from 2021.
  • Sanofi total liabilities for 2021 were $60.588B, a 3.23% increase from 2020.
Sanofi Annual Total Liabilities
(Millions of US $)
2023 $56,400
2022 $54,334
2021 $60,588
2020 $58,694
2019 $60,063
2018 $61,853
2017 $46,984
2016 $51,953
2015 $48,981
2014 $54,666
2013 $51,871
2012 $55,219
2011 $60,971
2010 $42,461
2009 $44,074
Sanofi Quarterly Total Liabilities
(Millions of US $)
2024-09-30
2024-06-30 $61,123
2024-03-31
2023-12-31 $56,400
2023-09-30
2023-06-30 $57,144
2023-03-31
2022-12-31 $54,334
2022-09-30
2022-06-30 $53,766
2022-03-31
2021-09-30
2021-03-31
2020-09-30
2020-03-31
2019-09-30
2019-03-31
2018-03-31
2017-12-31 $46,984
2017-09-30
2017-06-30 $48,495
2017-03-31
2016-12-31 $51,953
2016-09-30
2016-06-30 $50,568
2016-03-31
2015-09-30
2015-06-30 $45,519
2014-06-30 $53,436
2013-06-30 $53,270
2012-06-30 $58,329
2012-03-31 $0
2011-12-31 $60,971
2011-09-30
2011-06-30 $67,621
2011-03-31
2010-12-31 $42,461
2010-09-30
2010-06-30 $42,969
2010-03-31
2009-12-31 $44,074
2009-09-30
2009-06-30 $43,552
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $135.190B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.423B 80.52
Novo Nordisk (NVO) Denmark $502.334B 38.34
Johnson & Johnson (JNJ) United States $385.533B 15.64
AbbVie (ABBV) United States $359.539B 18.93
Merck (MRK) United States $258.042B 17.12
Novartis AG (NVS) Switzerland $223.511B 14.86
AstraZeneca (AZN) United Kingdom $221.444B 19.73
Pfizer (PFE) United States $159.177B 10.89
Innoviva (INVA) United States $1.205B 6.69